Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 446 (TSX: $AVCN.TO) (TSX: $HEXO.TO) (TSX: $ZENA.TO) (OTC: $EHVVF)
Delta, Kelowna, BC, July 24, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07241AVCN-HEXO-ZENA-EHVVF.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that the Company's research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada. The NSERC Alliance grants will be used to expand the investigators' collaborative research with Avicanna.
For the past three years, Dr. Christine Allen's research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna's cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation. Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.
A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna's research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna's naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.
Dr Jibran Khokhar, commented, "This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures."
HEXO Corp (TSX: HEXO) (NYSE: HEXO) announced the launch of its line of vape products to both adult-use and medical consumers, across Canada.
“At HEXO, we pride ourselves in ensuring our consumers have access to high-quality, reliable and consistent cannabis products,” said Sebastien St. Louis, CEO and co-founder of HEXO Corp. “We are thrilled to launch our vape products across Canada as we continue to focus on innovation and launching additional 2.0 products across all of our brands.”
Prior to releasing its line of vapes, the Company conducted testing to evaluate the taste, tolerability of effects and short-term undesired effects of its proprietary terpene blends.
HEXO’s vape products currently include three ready-to-use vape pens and four 510-thread cartridges, in popular strain-inspired terpene blends. HEXO vapes are available across Canada to both adult-use and medical consumers.
Zenabis Global Inc. (TSX: ZENA) today announced initial shipments of its Re-Up 510-Threaded Vaporizer line.
This week, Zenabis completed first shipments of this new product line, which is produced at Zenabis Atholville using product cultivated and extracted by Zenabis, with no requirement for third-party processing. Currently, the product offering includes two high THC products and one CBD product. Zenabis currently has listings of this product in five provinces and anticipates listings in an additional three provinces by the end of August.
Zenabis anticipates that its 510-Threaded Vaporizer line will contribute meaningfully to net revenue from August 2020 onward given consumer preference for the Re-Up 510-Threaded Vaporizer line of products. Thus far, all offers made under the Re-Up 510 Threaded Vaporizer line have been accepted by provincial counterparties. Zenabis has focused on achieving differentiation in this product line through:
● A focus on competitive, best-in-class pricing (targeting lowest retail pricing versus competitors in all available provincial markets); and
● Products based on terpene flavour profile, as opposed to cultivar.
Zenabis created this product line with a focus on consumer education and experience. The Re-Up 510-Threaded Vaporizer line of products was developed by our product development team to assist consumers in better understanding the botanical nature of terpenes. Each vaporizer cartridge type was developed with a purposefully curated selection of terpenes with complementary flavour profiles and similar characteristics. The initial launch of the
Re-Up 510-Threaded Vaporizer product line will include two high THC vaporizer cartridges: (i) Lemon and Lavender; and (ii) Hops and Spice, as well as one high CBD vaporizer cartridge, Pine and Berry. The Re-Up 510-Threaded Vaporizers product line will be available in two formats, 0.5g and 1.0g, and fit all standard 510 thread vaporizer pens.
Kevin Coft, Chief Executive Officer of Zenabis, stated, "We are very excited to have completed initial shipments under this product line, especially given that this was achieved through full, internalized production of these products at Zenabis Atholville utilizing in-house extraction and filling. We believe that the Re-Up 510-Threaded Vaporizer line is a strong complement to our existing, premium Pax Era line of vaporizer cartridges." Olen Vanderleeden, Senior Vice President of Zenabis added, "Based on indications from provincial counterparties and considering our competitive pricing, Zenabis anticipates incremental monthly revenue in excess of one million dollars per month once production at Zenabis Atholville rises to a level to meet consumer demand."
Ehave, Inc. (OTC : EHVVF) and its subsidiary PsyTech announced today an upcoming Psychedelic Industry webinar for investors and interested individuals. PsyTech was incubated by iCAN (Israel-cannabis) and developed by the team behind CannaTech, the premier international cannabis summit. Leveraging the highly relevant experience of iCAN, PsyTech is positioned to lead the global psychedelic conversation forward.
Ehave CEO Ben Kaplan said, "Our PsyTech Conferences have been very popular with investors, as a result of their insight on the industry. Psychedelic medicine has garnered a tremendous amount of attentions since The U.S. Food and Drug Administration (FDA) authorized Breakthrough Therapy Designation to both Compass Pathways' and Usona Institute's psilocybin therapy for depression in 2018." Mr. Kaplan continued, "The mainstream media started talking about it late last year after a group of private donors donated $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine. We expect our complimentary webinar on July 29 will continue our trend of providing important information on psychedelic medicine to investors.''
The virtual investor webinar titled Mystical Experience, Religion, and Psychedelics is open to individual investors, institutional investors, advisors, analysts and the Psychedelic Community. The program opens at 12:00 PM ET on Wednesday, July 29th.
Speakers for the PsyTech Virtual Investor Conference include:
Irie Selkirk - Moderator
Director of Rise Wellness Retreat and Co-Founder of Sansero Life Sciences
Pastor James Lindberg
An Ordained Clergy Person at The Evangelical Lutheran Church in America
Rabbi Zac Kamenetz
Founder and CEO of Shefa: Psychedelic Therapy Grounded in Jewish Spirituality
William A. Richards
Psychologist - The Center for Psychedelic And Consciousness Research At The Johns Hopkins University School Of Medicine
There are no fees to log-in, or attend the live presentations.
REGISTER NOW AT https://www.psytech.biz/psytech-mystical-experience-july-29th/
Please support our partner organization, Mind Medicine Australia, by registering for their upcoming summit on psychedelic therapies for mental illness. MMA is offering a special 10% discount code to the PsyTech community. Just use the code ‘MMA2020’ on their website when purchasing an event package.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411